Tedesco MM, Terashima M, Blankenberg FG, Levashova Z, Spin JM, Backer M, Backer J, Sho M, Sho E, McConnell MV, Dalman RL. (2009) Expression During Experimental Aortic Aneurysm Progression Analysis of In Situ and Ex Vivo Vascular Endothelial Growth Factor Receptor Arterioscler. Thromb. Vasc. Biol. DOI:10.1161/ATVBAHA.109.187757.
Levashova Z, Backer M, Horng G, Felsher D, Backer JM, Blankenberg FG (2009). SPECT and PET Imaging of EGF Receptors with Site-Specifically Labeled EGF and Dimeric EGF. Bioconjug. Chem. 20, 742–749.
Saban R, Saban MR, Maier J, Fowler B, Tengowski M, Davis CA, Wu XR, Culkin DJ, Hauser P, Backer J, Hurst RE. (2008) Urothelial expression of Neuropilins and VEGF receptors in control and interstitial cystitis patients.American Journal of Physiology - Renal Physiology. 295(6):F1613-23, 2008
Saban MR, Backer JM, Backer MV, Maier J, Fowler B, Davis CA, Simpson C, Wu X-R, Birder L, Freeman MR, Soker S, and Saban R (2008). VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are up-regulated in inflammation. Am. J. Physiol. Renal. 295(1):F60-72.
Levenson RM, Lynch DT, Kobayashi H, Backer JM, and Backer MV (2008) Multiplexing with multispectral imaging: from mice to microscopy. ILAR J. 49, 78-87
Levashova Z, Backer M, Backer JM, Blankenberg FG (2008). Direct site-specific labeling of the Cys-tag moiety in scVEGF with Technetium 99m. Bioconjugate Chem. 19, 1049-1054
Backer MV, Levashova Z, Levenson R, Blankenberg FG, Backer JM. (2008) Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins. Methods in Molecular Medicine. Peptide-based Drug Design. Humana Press, New York, NY. Ed: L. Otvos. Vol. 494, p.275-94.
Backer, M. V., Patel, V., Jehning, B. T., Claffey, K., Karginov, V. A. and Backer, J.M. (2007b) Inhibition of anthrax protective antigen outside and inside the cell. Antimicrob. Agent. Chemother. 51, 245-251.
Blankenberg, F.G., Backer, M. V., Levashova, Z., Vimalkumar Patel, V., and Backer, J.M. (2006) In vivo tumor angiogenesis imaging with site-specific labeled 99mTc-HYNIC-VEGF. Eur. J. Nucl. Med. Mol. Imag. 33, 841-848.
Backer, M. V., Patel, V., Jehning, B. T., Claffey, K., and Backer, J.M. (2006a) Surface immobilization of active vascular endothelial growth factor via a cysteine-containing tag. Biomaterials 27, 5452-5458.
Thirumamagal, B. T. S., Zhao, X. B., Bandyopadhyaya, A. K., Narayanasamy, S., Johnsamuel, J., Tiwari, R., Golightly, D. W., Patel, V., Jehning, B. T., Backer, M. V., Barth, R. F., Lee, R. J., Backer, J. M., and Tjarks, W. Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT). Bioconjugate Chem. (2006) DOI 10.1021/bc060075 (on line 8.15.2006).
Wu, G., Barth, R., Yang, W., Lee, R. J., Tjarks W., Backer, M.V., and Backer, J.M. (2006), Boron containing macromolecules and nanovehicles as delivery agents for neutron capture therapy. Anti-Cancer Agents Med. Chem. 6, 167-184.
Backer, M.V. Patel, V., Jehning, B., and Backer, J.M. (2006b) Self-Assembled “Dock and Lock” system for linking payloads to targeting proteins. Bioconjugate Chem. 17, 912-919.
Backer, M.V., Gaynutdinov, T.I., Patel V., Bandyopadhyaya A.K., Thirumamagal, B.T.S, Tjarks W., Barth, R., Claffey, K.P., and Backer, J.M. (2005) Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol. Cancer Ther. 4, 1423-1429.
Backer, M. V., Elliot, J., Gaynutdinov, T. I., and Backer, J. M. (2004a) Assembly of targeting complexes driven by a single-chain antibody. J. Immunol. Meth. 289, 37-45.
Blankenberg, F. G., Mandl, S., Cao, Y.-A., O’Connell-Rodwell, C., Contag, C., Mari, C., Gaynutdinov, T. I., Vanderheyden, J.-L., Backer, M. V., and M. Backer, J. M. (2004) Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor (VEGF). J. Nuclear Med. 45, 1373-1380.
Backer, M. V., Gaynutdinov, T., Patel, V., Jehning, B., Myshkin, E., and Backer, J. (2004) Adapter protein for site-specific conjugation of payloads for targeted drug delivery. Bioconj. Chem. 15, 1021-1029.
Backer, M. Gaynutdinov, T., Gorshkova, I., Crouch, R., Hu, T., Aloise, R., Arab, M., Przekop, K., and Backer, J. (2003) Humanized docking system for assembly of targeting drug delivery complexes. J. Controlled Release 89, 499-511.
Gaynutdinov, T., Myshkin, E., Backer, J., and Backer, M. (2003) Chimeric ribonuclease as a source of human adapter protein for targeted drug delivery. Prot. Eng. 16, 771-775.
Backer, M., Aloise, R., Przekop, K., Stoletov, K., and Backer, J. (2002) Molecular vehicles for targeted drug delivery. Bioconjugate Chem. 13, 462-467.
Backer, M., Gaynutdinov, T., Aloise, R., Przekop, K., and Backer, J. (2002) Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery. Prot. Exp. Purif. 26, 455-461.
Backer, M. V. and Backer, J. M. (2001) Functionally active VEGF fusion proteins. Prot. Exp. Purif. 23, 1-7.
Gaidamakova, E. K., Backer, M. V., and Backer, J. M. (2001) Molecular vehicle for target-mediated delivery of therapeutics and diagnostics. J. Control. Release 74, 341-347.
Backer, M. V. Budker, V. G., and Backer, J. M. (2001) Shiga-like toxin-VEGF fusion are selectively cytotoxic to endothelial cells overexpressing VEGFR-2. J. Control. Release 74, 349-355.
Backer, M. V. and Backer, J. M. (2001a) Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins. Bioconjugate Chem. 12, 1066-1073.